FDA Adjusts Thinking On Drug/Diagnostic Co-Development Draft Guidance
This article was originally published in The Gray Sheet
Executive Summary
FDA will be more flexible about the schedule it expects sponsors to follow for drug/diagnostic co-development than the agency suggested in a 2005 "concept paper" on the subject